Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Papillomavirus Infections

Conditions

Papillomavirus Infections

Trial Timeline

May 3, 2007 → Feb 4, 2008

NCT ID

NCT00380367

About Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00380367. Target conditions include Papillomavirus Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01209325	Phase 2	Completed	Jun 28, 2011	Dec 12, 2017	Anal Cancer
NCT00733122	Phase 3	Withdrawn	Oct 1, 2009	Oct 1, 2013	HPV Infections
NCT00635830	Phase 1	Completed	Mar 1, 2008	Apr 1, 2008	HPV Infections
NCT00380367	Phase 3	Completed	May 3, 2007	Feb 4, 2008	Papillomavirus Infections

Competing Products

20 competing products in Papillomavirus Infections

See all competitors

Product	Company	Stage	Hype Score
AAVLP-HPV + Placebo	2A Pharma	Phase 1	25
9vHPV vaccine	Merck	Phase 3	77
Human Papillomavirus 9-valent Vaccine, Recombinant	Merck	Approved	85
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)	Merck	Phase 3	77
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)	Merck	Phase 3	77
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administration	Merck	Pre-clinical	23
Gardasil	Merck	Approved	85
Gardasil	Merck	Phase 2	52
9vHPV Vaccine	Merck	Phase 3	77
9vHPV Vaccine + mRNA-1273 Vaccine	Merck	Phase 3	77
V503 + GARDASIL	Merck	Phase 3	77
9vHPV Vaccine	Merck	Phase 3	77
Gardasil vaccine	Merck	Pre-clinical	23
V503	Merck	Phase 3	77
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) + Placebo	Merck	Phase 3	77
V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)	Merck	Phase 3	77
9vHPV vaccine	Merck	Phase 3	77
Gardasil™ + Placebo	Merck	Phase 3	77
V503 + Gardasil	Merck	Phase 3	77
9vHPV vaccine	Merck	Phase 3	77

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved